The initial expected action date was March 28, 2026, but a slight delay moved the target to April 10, 2026
If you are considering either medication and want guidance on which option is realistic for your situation, a telehealth provider specializing in metabolic health can review your clinical profile and help you navigate the access landscape
Subgroup analysis by dosage showed that the use of 10 mg tirzepatide was associated with an increased risk of the composite of gallbladder or biliary disease (RR 1.91, [95% CI] 1.14 to 3.19
CJC-1295/Ipamorelin produces a larger, longer, dual-pathway growth hormone pulse with a comparable safety profile to Sermorelin
Nat Biotechnol 38(11):12261228
Supplementing with 15 to 30 mg daily during active weight loss is a reasonable strategy, though testing zinc levels through a simple blood test provides more precise guidance